Skip to main content

Vertex Pharmaceuticals, Inc. (VRTX)

NASDAQ: VRTX · IEX Real-Time Price · USD
183.52 -3.57 (-1.91%)
Oct 22, 2021 4:00 PM EDT - Market closed
Market Cap47.61B
Revenue (ttm)6.68B
Net Income (ttm)1.99B
Shares Out258.99M
EPS (ttm)7.59
PE Ratio24.20
Forward PE14.01
Ex-Dividend Daten/a
Previous Close187.09
Day's Range182.88 - 187.15
52-Week Range176.36 - 242.99
Price Target258.45 (+40.8%)
Est. Earnings DateOct 28, 2021

About VRTX

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitr...

IPO DateJul 24, 1991
CEOReshma Kewalramani
Stock ExchangeNASDAQ
Ticker SymbolVRTX
Full Company Profile

Financial Performance

In 2020, VRTX's revenue was $6.21 billion, an increase of 49.07% compared to the previous year's $4.16 billion. Earnings were $2.71 billion, an increase of 130.42%.

Financial Statements

Analyst Forecast

According to 28 analysts, the average rating for VRTX stock is "Buy." The 12-month stock price forecast is 258.45, which is an increase of 40.83% from the latest price.

Price Target
(40.83% upside)
Analyst Consensus: Buy


Vertex to Announce Third-Quarter 2021 Financial Results on November 2

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third-quarter 2021 financial results on Tuesday, November 2, 2021 after the financial markets close. The compa...

15 hours ago - Business Wire

3 of the Best Stocks to Buy Now With $500

Five Ben Franklins will put you in a great position to make a lot more with these stocks.

Other symbols:MTTRNVDA
17 hours ago - The Motley Fool

Can Vertex (VRTX) Climb 42% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for Vertex (VRTX) points to a 42.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in...

1 day ago - Zacks Investment Research

If I Could Only Own 1 Healthcare Stock, This Is What It Would Be

Investing gets simple if you have to put all of your eggs in one basket.

1 day ago - The Motley Fool

Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $185.49, marking a +0.04% move from the previous day.

2 days ago - Zacks Investment Research

Is This Beaten Down Biotech a Bad News Buy?

It has lagged the market over the last five years but with a promising gene therapy, is Sarepta worth another look?

Other symbols:NVSSRPTUTHR
2 days ago - The Motley Fool

Why Are Investors Ignoring Vertex's Good News?

Vertex announced promising trial data for its type 1 diabetes treatment candidate.

2 days ago - The Motley Fool

Vertex's (VRTX) Early Type I Diabetes Study Data Promising

Vertex's (VRTX) single infusion drug candidate, VX-880, for type I diabetes shows restoration of insulin production and robust improvements in multiple measures in a phase I/II study

3 days ago - Zacks Investment Research

Here's Why Vertex Pharmaceuticals (VRTX) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

3 days ago - Zacks Investment Research

Vertex to Present Long-Term Data Demonstrating Significant Benefits of Treatment With CFTR Modulators at North Americ...

BOSTON--(BUSINESS WIRE)--Vertex announced that five abstracts about its cystic fibrosis (CF) medicines will be presented at the 2021 North American Cystic Fibrosis Conference.

3 days ago - Business Wire

Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Nove...

BOSTON--(BUSINESS WIRE)--Vertex today announced positive data for the first patient from the Phase 1/2 clinical trial of VX-880, for the treatment of type-1 diabetes.

4 days ago - Business Wire

3 No-Brainer Stocks to Invest $500 In Right Now

You won't need a boatload of cash to build wealth with these top-tier companies.

Other symbols:BAC
4 days ago - The Motley Fool

2 Stocks You'll Probably Never Want to Sell

Both are biotech stocks with tremendous long-term opportunities.

Other symbols:TWST
5 days ago - The Motley Fool

3 No-Brainer Biotech Stocks to Buy Right Now

Regeneron Pharmaceuticals, Vertex Pharmaceuticals, and Viatris should have plenty of room to run.

Other symbols:REGNVTRS
6 days ago - The Motley Fool

3 Highly Profitable Stocks Wall Street Thinks Will Soar 39% or More

There are good reasons behind analysts' optimism about these stocks.

Other symbols:BIIBBMY
1 week ago - The Motley Fool

Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know

Vertex Pharmaceuticals (VRTX) closed at $181.34 in the latest trading session, marking a +0.63% move from the prior day.

1 week ago - Zacks Investment Research

Why the Earnings Surprise Streak Could Continue for Vertex (VRTX)

Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

1 week ago - Zacks Investment Research

3 Biotech Stocks You Can Buy and Hold for the Next Decade

Balance risk and reward with these proven drugmakers.

Other symbols:REGNSGEN
1 week ago - The Motley Fool

3 Top Healthcare Stocks That Could Rise More Than 40% in 12 Months

One is at the beginning of its story. The others may enter new growth chapters down the road.

Other symbols:BIIBTDOC
1 week ago - The Motley Fool

VRTX vs. PRTA: Which Stock Should Value Investors Buy Now?

VRTX vs. PRTA: Which Stock Is the Better Value Option?

Other symbols:PRTA
1 week ago - Zacks Investment Research

2 Beaten-Down Growth Stocks to Buy Hand Over Fist

For those focused on the long game, the recent poor stock performances of Vertex Pharmaceuticals and Veeva Systems may present buying opportunities.

Other symbols:VEEV
1 week ago - The Motley Fool

3 Unstoppable Stocks to Buy in October

Their long-term prospects make these stocks great picks.

Other symbols:NVDASQ
2 weeks ago - The Motley Fool

Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $180.02, marking a -0.49% move from the previous day.

2 weeks ago - Zacks Investment Research

3 Top Healthcare Stocks to Buy for October

They're bargains now -- but their prices could multiply down the road.

Other symbols:ISRGTDOC
2 weeks ago - The Motley Fool

Vertex Needs to Sell or Make a Big Acquisition

Should investors holding shares of Vertex Pharmaceuticals Incorporated ( VRTX , Financial) follow the axiom, “Good things come to those who wait?”

2 weeks ago - GuruFocus